BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28920661)

  • 1. In search of the philosopher’s stone: The ALCHEMIST study for lung cancer.
    Veeramachaneni N; Wigle D; Boughey JC
    Bull Am Coll Surg; 2017 Mar; 102(3):37-8. PubMed ID: 28920661
    [No Abstract]   [Full Text] [Related]  

  • 2. Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.
    Alden RS; Mandrekar SJ; Oxnard GR
    Chin Clin Oncol; 2015 Sep; 4(3):37. PubMed ID: 26408304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted treatment tested as potential cancer cure.
    Hayden EC
    Nature; 2011 Nov; 479(7373):281. PubMed ID: 22094668
    [No Abstract]   [Full Text] [Related]  

  • 4. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
    Govindan R; Mandrekar SJ; Gerber DE; Oxnard GR; Dahlberg SE; Chaft J; Malik S; Mooney M; Abrams JS; Jänne PA; Gandara DR; Ramalingam SS; Vokes EE
    Clin Cancer Res; 2015 Dec; 21(24):5439-44. PubMed ID: 26672084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer.
    Lourdes LS; Jalal SI; Hanna N
    Oncologist; 2015 Sep; 20(9):975-8. PubMed ID: 26268739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-over-it's a feature, not a bug.
    Engelsberg A
    Ann Oncol; 2015 Sep; 26(9):2000-2002. PubMed ID: 26078468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.
    Peled N; Zach L; Liran O; Ilouze M; Bunn PA; Hirsch FR
    J Thorac Oncol; 2013 Dec; 8(12):e112-3. PubMed ID: 24389447
    [No Abstract]   [Full Text] [Related]  

  • 8. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.
    Kim SJ; Kim DW; Kim TM; Lee SH; Heo DS; Bang YJ
    J Clin Oncol; 2012 Jun; 30(16):e147-50. PubMed ID: 22508824
    [No Abstract]   [Full Text] [Related]  

  • 9. NSCLC drug targets acquire new visibility.
    Friedrich MJ
    J Natl Cancer Inst; 2011 Mar; 103(5):366-7. PubMed ID: 21357596
    [No Abstract]   [Full Text] [Related]  

  • 10. [Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].
    Giroux Leprieur E; Wislez M
    Bull Cancer; 2016 Feb; 103(2):125-6. PubMed ID: 26822904
    [No Abstract]   [Full Text] [Related]  

  • 11. [Therapeutic impact of molecular diagnosis in metastatic non-small cell lung cancer: targeted therapies in 2013].
    Pecuchet N; Bigot F; Henni M; Fabre E
    Rev Pneumol Clin; 2014; 70(1-2):38-46. PubMed ID: 24566025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crizotinib (xalkori) for non-small cell lung cancer.
    Med Lett Drugs Ther; 2012 Feb; 54(1383):11-2. PubMed ID: 22354221
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of crizotinib inhibiting specific molecular pathways in non-small-cell lung carcinoma.
    Mirshahidi HR; Mirshahidi S
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):375-85. PubMed ID: 25797684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib.
    Toyokawa G; Hirai F; Inamasu E; Yoshida T; Nosaki K; Takenaka T; Yamaguchi M; Seto T; Takenoyama M; Ichinose Y
    J Thorac Oncol; 2014 Dec; 9(12):e86-7. PubMed ID: 25393798
    [No Abstract]   [Full Text] [Related]  

  • 15. Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.
    Costa DB; Kobayashi S
    J Thorac Oncol; 2012 Mar; 7(3):623-5. PubMed ID: 22334013
    [No Abstract]   [Full Text] [Related]  

  • 16. [Personalized treatment in non-small cell lung cancer].
    Campos-Parra AD; Cruz-Rico G; Arrieta O
    Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
    [No Abstract]   [Full Text] [Related]  

  • 17. [Crizotinib for ROS1-rearranged non-small cell lung cancer patients].
    Domblides C; Antoine M; Lavole A; Cadranel J; Wislez M
    Bull Cancer; 2017 Apr; 104(4):303-310. PubMed ID: 28237354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cystic Brain Metastases in NSCLC Harboring the EML4-ALK Translocation after Treatment with Crizotinib.
    Saraceni C; Li PM; Gainor JF; Stopyra GA; Friedman EL
    J Thorac Oncol; 2015 Jul; 10(7):1116-7. PubMed ID: 26134230
    [No Abstract]   [Full Text] [Related]  

  • 19. Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer.
    Guo L; Zhang H; Shao W; Chen B
    Drug Des Devel Ther; 2015; 9():5491-7. PubMed ID: 26491259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No].
    Girard N
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S96-9. PubMed ID: 26118885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.